Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 9, 2007, Pages 870-873

  Pace Asciak, Pia Z ^a,b   Payne, Richard J ^a   Eski, Spiro J ^a   Walfish, Paul ^a   Damani, Manzur ^a   Freeman, Jeremy L ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; SODIUM IODIDE I 131;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COST CONTROL; DEMOGRAPHY; DRUG COST; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METASTASIS AGE COMPLETENESS OF RESECTION INVASION AND SIZE SCORE; POLICY; RETROSPECTIVE STUDY; SCORING SYSTEM; THYROID CANCER; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; COST SAVINGS; EVIDENCE-BASED MEDICINE; FEMALE; HOSPITAL COSTS; HUMANS; IODINE RADIOISOTOPES; LENGTH OF STAY; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASM INVASIVENESS; ONTARIO; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34548718888     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.9.870     Document Type: Article

References (22)

1. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999) [published online ahead of print May 21, 2002]. World J Surg. 2002;26(8):879-885. doi:10.1007/s200268-002-6612-1.
2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma. Surgery. 1993;114(6):1050-1057.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83(12):2638-2648.
4. DeGroot LJ, Kaplan EL, Straus FH, Shukla MS. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg. 1994;18(1):123-130.
5. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297-306.
6. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biological significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43-63.
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [published correction appears in Am J Med. 1995;98(2):215]. Am J Med. 1994;97(5):418-428.
8. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment on well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75(3):714-720.
9. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;14(6):1063-1075.
10. Tenenbaum F, Corone C, Schlumberger M, Parmentier C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease [letter]. Eur J Cancer. 1996;32A(7):1262.
11. Woodrum DT, Gauger PG. Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol. 2005;89(3):114-121.
12. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668-3676.
13. Cushing SL, Palme CE, Audet N, Eski S, Walfish PG, Freeman JL. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope. 2004;114(12):2110-2115.
14. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-424.
15. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947-953.
16. Kjellman P, Zedenius J, Lundell G, et al. Predictors of outcome in patients with papillary thyroid carcinoma [published online ahead of print February 3, 2006]. Eur J Surg Oncol. 2006;32(3):345-352. doi:10.1016/j.ejso.2005.12.008.
17. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin. 1999;49(1):8-31.
18. Caldwell CB, Ehrlich E. Outpatient treatment of thyroid cancer using high doses of iodine 131. Can Assoc Radiol J. 1999;50(5):331-336.
19. Rutar FJ, Augustine SC, Colcher D, et al. Outpatient treatment with 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42(6):907-915.
20. 131I) therapy for thyroid carcinoma. JAMA. 2000;283(17):2272-2274.
21. Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19(3):685-718.
22. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancy in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644.